By IDSE News Staff
The FDA granted a new indication for Merck’s two doravirine-based HIV therapies that allows adults who are virologically suppressed to switch to doravirine (Pifeltro; DOR) or doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo; DOR/3TC/TDF).
Infected adults with viral loads less than 50 copies/mL and on a stable antiretroviral treatment (ART) regimen with no history of treatment failure and no known substitutions associated with resistance to DOR can switch